Adaptimmune options lead anti-cancer T-cell candidate to Glaxo
Adaptimmune Ltd. (enhances T-cells’ natural ability to destroy disease-causing cells) licensed GlaxoSmithKline PLC an option on its lead cancer candidate, Phase I/II NYESO1.
- Gene Therapy, Cell Therapy
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.